Takeda Ventures was among the participants in a $46.5m round closed nearly a year after its parent company launched a partnership with the Institut Curie spinout.
Egle Therapeutics, a France-based T-cell therapy developer spun out of Institut Curie, closed a €40m ($46.5m) series A round late last month that included Takeda Ventures, the strategic investment arm of pharmaceutical firm Takeda.
Public investment bank Bpifrance’s InnoBio 2 fund co-led the round with life sciences investment firm LSP, and it also featured venture capital fund Fund+ and investment firm Bioqube Ventures.
Egle is working on immunotherapies designed to fight cancer and autoimmune diseases by targeting immune suppressor regulatory T-cells (Tregs). Spun out in 2020, it formed a research partnership with Takeda in November the same year.
Takeda Ventures senior partner Sacha Mann has taken a board seat at Egle alongside Felice Verduyn-van Weegen and Vincent Brichard of LSP and Jean-Francois Morin of InnoBio 2, while Philippe Monteyne of Fund+, Jacques Mizrahi of Bioqube Ventures and Elisa El Nouchi of InnoBio 2 are taking board observer roles.
Luc Boblet,…
